KAKEN PHARMACEUTICAL CO., LTD.
4521・Prime Market・Pharmaceuticals
Business
The Kaken Pharmaceutical Group consists of two business segments: the Pharmaceutical Business, which is responsible for the manufacture and sale of pharmaceuticals, medical devices, and agricultural chemicals, and the Real Estate Business, centered on Bunkyo Green Court. In the Pharmaceutical Business, the company focuses primarily on the dermatology and orthopedics fields, expanding its product lineup through both in-house drug discovery and active licensing-in from domestic and overseas sources. In agricultural chemicals, the company's mainstay product is "Polyoxin," a microbially-derived natural substance pesticide. The group structure includes four consolidated subsidiaries (Kaken Pharma, Arsam, KAKEN INVESTMENTS, and Ardy), and the company advances its business through both a domestic sales network and overseas license-out activities. Its main customers are medical institutions and healthcare professionals, with distribution centered on wholesalers (Alfresa, Mediceo, and Suzuken).
Business Model
The core of revenue is the domestic sale of pharmaceuticals and medical devices, delivered to medical institutions through a specialized MR network in the dermatology and orthopedics fields. In addition, revenue is supplemented by upfront payments, milestones, and royalty income from overseas out-licensing of proprietary drug discoveries (Clenafin (Jublia) in North America, Europe, and Asia; Ecroc in South Korea, etc.). The Real Estate Business (Bunkyo Green Court Real Estate Leasing) functions as a stable revenue source independent of fluctuations in the Pharmaceutical Business's performance. R&D expenses reach approximately 27% of net sales (¥20,585 million), characterized by aggressive investment in enriching the pipeline.
Company Strengths
As of the end of FY2026 (ending March 2026), the company held over 20 valid contracts combining technology in-licensing, sales in-licensing, and co-promotion. It newly in-licensed Ecterly, gMSC1, Nabenibart, NM81, and others, building a robust pipeline that includes plans to file for approval of KP-001 and KAR during the first half of FY2026. Strategic alliances with domestic and overseas companies and research institutions have established a framework that complements its own research capabilities.
Clenafin (Jublia) has been out-licensed to North America (Bausch Health), South Korea (Dong-A ST), China/Hong Kong/Macau, and Europe (Almirall), and in FY2026 (ending March 2026) it obtained manufacturing and marketing approval in Germany (its second European country). Ecroc has been launched in South Korea. KP-723 has been out-licensed worldwide to Johnson & Johnson, giving the company a track record of global intellectual property monetization.
As of the end of FY2026 (ending March 2026), the equity ratio stood at 82.8%, cash and cash equivalents were ¥50,705 million, and the current ratio was 452.1%, indicating extremely high financial soundness. With a financial structure close to debt-free management, the company covers R&D expenses of ¥20,585 million and capital expenditures of ¥3,684 million with its own funds, while also maintaining capacity for additional M&A and in-licensing investments.
ENVALITH's Perspective
Performance Trend
Revenue fluctuated sharply, moving from ¥72,044 million in FY2024 to ¥94,035 million in FY2025 (+30.5%) and then to ¥76,871 million in FY2026 (ending March 2026) (-18.3%). The surge in FY2025 was mainly attributable to a lump-sum licensing payment (NM26, STAT6 inhibitor), and the reversal of this effect in FY2026 caused overseas sales to decline by 51.7%. Cost of sales increased 3.9% year on year to ¥36,879 million, while R&D expenses expanded to ¥20,585 million (up 9.9% year on year). Total selling, general and administrative expenses of ¥40,891 million exceeded gross profit of ¥39,991 million, resulting in an operating loss of ¥899 million. Net income of ¥2,144 million (down 84.6% year on year) was supported by extraordinary income comprising a gain on sale of fixed assets of ¥1,366 million and a gain on sale of investment securities of ¥2,016 million, together with a tax effect from the reversal of deferred tax assets (adjustment to income taxes of -¥1,896 million). Operating cash flow deteriorated sharply to -¥11,079 million from ¥29,780 million in the prior period, mainly due to the payment of income taxes (¥10,654 million) related to the large licensing income recorded in the previous period.
Growth Strategy
Aiming for net sales of ¥100,000 million in FY2031 through three transformations spanning R&D, overseas expansion, and management foundation
KP-001, a treatment for refractory vascular malformations, and KAR, a treatment for head lice infestation with insufficient response to existing treatments, both achieved their primary endpoints in domestic Phase III trials. A manufacturing and marketing approval application is planned within the first half of FY2026, and the domestic launch following approval acquisition is expected to become a pillar of medium-term earnings.
"Ecterly" (for hereditary angioedema) has already been launched domestically. "ESK-001" (dermatology) has had its Phase III results announced by Almirall, and domestic approval preparations are underway. "Nabenivart," "gMSC1," and the "Silk Elastin Wound Dressing Sheet" are also progressing in their respective phases, advancing the diversification of the product lineup.
Efforts to diversify the overseas revenue base are advancing, including the approval of "Jublia (Clenafin)" in Germany (the second European country), the launch of "Ecroc" in South Korea, and the acquisition of sales rights in the Asian region through the strategic licensing and joint development agreement for "NM81" with Numab. The one-time milestone payment upon achievement is factored in as a key revenue growth driver in the earnings forecast for FY2027 (ending March 2027).
R&D expenses for FY2026 (ending March 2026) reached a record high of ¥20,585 million (up 9.9% year on year). The April 2025 revision of the Long-Term Management Plan explicitly stated an increase in the strategic investment amount for the continuous launch of groundbreaking and innovative new drugs. Although this pressures short-term profit, the company continues its policy of prioritizing the accumulation of pipeline value.
The annual dividend for FY2026 (ending March 2026) was maintained at ¥190 (unchanged from the previous period). The dividend payout ratio reached 335.9%, significantly exceeding net income. For FY2027 (ending March 2027), a dividend of ¥190 is also forecast (payout ratio of 110.7%). Share buybacks (¥2,343 million in FY2026, ending March 2026) and cancellation (1,800,000 shares) were also carried out, and the revision of the Long-Term Management Plan explicitly stated a strengthening of shareholder returns.
Last updated: July 19, 2026